[Answer] Which of the following is the routine schedule for vaccinating adolescents with MCV4?

Answer: One dose at age 11 to 12 years followed by a booster dose at age 16 years.
Which of the following is the routine schedule for vaccinating adolescents with MCV4?

Meningococcal vaccine refers to any of the vaccines used to prevent infection by Neisseria meningitidis. Different versions are effective against some or all of the following types of meningococcus: A B C W-135 and Y. The vaccines are between 85 and 100% effective for at least two years. They result in a decrease in meningitis and sepsis among populations where they are widely used. They are gi…

Meningococcal vaccine refers to any of the vaccines used to prevent infection by Neisseria meningitidis. Different versions are effective against some or all of the following types of meningococcus: A B C W-135 and Y. The vaccines are between 85 and 100% effective for at least two years. They result in a decrease in meningitis and sepsis among populations where they are widely used. They are given either by injection into a muscle or just under the skin. The World Health Organization recommends that countries with a moderate or high rate of disease or with frequent outbreaks should routinely vaccinate. In countries with a low risk of disease they recommend that high risk groups should be immunized. In the African meningitis belt efforts to immunize all people between the ages of one and thirty with the meningococcal A conjugate vaccine are ongoing. In Canada and the United States the vaccines effective against four types of meningococcus (A C W and Y) are recommended routinely for teenagers and others who are at high risk. Saudi Arabia requires vaccination with the quadrivalent vaccine for international travelers to Mecca for Hajj. Meningococcal vaccines are generally safe. Some people develop pain and redness at the injection site. Use in pregnancy appears to be safe. Severe allergic reactions occur in less than one in a million doses. The first meningococcal vaccine became available in the 1970s. It is on the World Health Organization’s List of Essential Medicines.

Neisseria meningitidis has 13 clinically significant serogroups classified according to the antigenic structure of their polysaccharide capsule. Six serogroups A B C Y W-135 and X are responsible for virtually all cases of the disease in humans.

Neisseria meningitidis has 13 clinically significant serogroups classified according to the antigenic structure of their polysaccharide capsule. Six serogroups A B C Y W-135 and X are responsible for virtually all cases of the disease in humans. Quadrivalent (Serogroups A C W-135 and Y) There are three vaccines available in the United States to prevent meningococcal disease all quadrivalent in nature targeting serogroups A C W-135 and Y: • three conjugate vaccines (MCV-4) Menactra Menveo and MenQuadfi. The pure polysaccharide vaccine Menomune MPSV4 was discontinued in the United States in 2017. Menveo and MenQuadfi are approved for medical use in the European Union. Menveo The first meningococcal conjugate vaccine (MCV-4) Menactra …

Leave a Reply